Generation Bio Co Total Liabilities
Generation Bio Co total liabilities. Based on the latest financial reports, Generation Bio Co (GBIO) has total liabilities worth $71.34 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Generation Bio Co (GBIO) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Generation Bio Co (2018–2024)
Total liabilities of Generation Bio Co from 2018 to 2024. This chart illustrates how Generation Bio Co's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Generation Bio Co to see how much of total assets are deployed in long-term investments.
Generation Bio Co Competitors by Total Liabilities
The table below lists competitors of Generation Bio Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
VerticalScope Holdings Inc
TO:FORA
|
Canada | CA$57.53 Million |
|
Cranswick PLC
LSE:CWK
|
UK | GBX648.40 Million |
|
Beaconsmind AG
PA:MLBMD
|
France | €1.90 Million |
|
TAEYANG Corporation
KQ:053620
|
Korea | ₩34.18 Billion |
|
Vintcom Technology PCL
BK:VCOM
|
Thailand | ฿857.29 Million |
|
Atakule Gayrimenkul Yatirim Ortakligi AS
IS:AGYO
|
Turkey | TL17.91 Million |
|
Burcelik Bursa Celik Dokum Sanayi AS
IS:BURCE
|
Turkey | TL70.44 Million |
|
Lesico Ltd
TA:LSCO
|
Israel | ILA507.38 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Generation Bio Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Generation Bio Co.
Liquidity & Leverage Metrics
Generation Bio Co Total Liabilities Ratios Explained
Generation Bio Co total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Generation Bio Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Generation Bio Co (2018–2024)
The table below shows the annual total liabilities of Generation Bio Co from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $144.99 Million | -15.52% |
| 2023-12-31 | $171.63 Million | +83.03% |
| 2022-12-31 | $93.77 Million | -1.32% |
| 2021-12-31 | $95.03 Million | +263.50% |
| 2020-12-31 | $26.14 Million | -81.42% |
| 2019-12-31 | $140.73 Million | +12.49% |
| 2018-12-31 | $125.11 Million | -- |
About Generation Bio Co
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise me… Read more